A systematic review of noninvasive preimplantation genetic testing for aneuploidy.

Noninvasive embryo testing aneuploidy in vitro fertilization preimplantation genetic testing for aneuploidy (PGT-A) spent blastocyst media (SBM)

Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
08 2023
Historique:
received: 18 05 2023
revised: 20 06 2023
accepted: 20 06 2023
medline: 1 8 2023
pubmed: 26 6 2023
entrez: 25 6 2023
Statut: ppublish

Résumé

Noninvasive and minimally invasive preimplantation genetic testing for aneuploidy (PGT-A) is a tool that may one day become the gold standard for embryonic chromosomal screening. Investigations on this topic have ranged from studying the culture media of embryos to the fluid inside the blastocoel, all in an attempt to find a reliable source of DNA without the need to biopsy the embryo. There is great interest across the board, both from those for and against biopsy, in a reliable test process that would give the patient and provider the same information possible from a biopsy without the risk. We aim to explore the current available research to better understand the utility and accuracy of PGT-A with these new sampling techniques. General concordance rates in comparison with biopsy-based PGT-A are promising, but it is clear that additional research and understanding are needed before adopting noninvasive and minimally invasive PGT-A as a widely used tool with strong clinical utility.

Identifiants

pubmed: 37356468
pii: S0015-0282(23)00616-7
doi: 10.1016/j.fertnstert.2023.06.013
pii:
doi:

Substances chimiques

Culture Media 0

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-239

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Cengiz Cinnioglu (C)

NextGen Genetics, Santa Clara, California. Electronic address: ccinnioglu@nextgengenetics.com.

Heather Glessner (H)

NextGen Genetics, Santa Clara, California.

Amy Jordan (A)

NextGen Genetics, Santa Clara, California.

Sydney Bunshaft (S)

NextGen Genetics, Santa Clara, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH